Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
TERT
cytokeratin 19
hepatocellular carcinoma
intrahepatic cholangiocarcinoma
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
27
12
2018
accepted:
22
04
2019
pubmed:
25
4
2019
medline:
23
2
2020
entrez:
25
4
2019
Statut:
ppublish
Résumé
The present study aimed to systematically compare clinicopathological and genetic features between keratin 19 (K19)-expressing hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Consecutive cases of HCC (n = 430) were classified into K19 Although K19
Substances chimiques
KRT19 protein, human
0
Keratin-19
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-393Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Kawai-Kitahata F, Asahina Y, Tanaka S et al. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J. Gastroenterol. 2016; 51; 473-486.
Nault JC, Mallet M, Pilati C et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 2013; 4; 2218.
Chianchiano P, Pezhouh MK, Kim A et al. Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. Hum. Pathol. 2018; 72; 127-134.
Totoki Y, Tatsuno K, Covington KR et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 2014; 46; 1267-1273.
Sung WK, Zheng H, Li S et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 2012; 44; 765-769.
Fujimoto A, Furuta M, Totoki Y et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 2016; 48; 500-509.
Zhao LH, Liu X, Yan HX et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat. Commun. 2016; 7; 12992.
Kim H, Choi GH, Na DC et al. Human hepatocellular carcinomas with ‘Stemness’ - related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011; 54; 1707-1717.
Chan AW, Tong JH, Chan SL et al. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 2014; 64; 935-950.
Lee CW, Lin SE, Tsai HI et al. Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma. Oncol. Lett. 2018; 15; 559-567.
Shibuya M, Kondo F, Sano K et al. Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma. J. Hepatobil. Pancreat. Sci. 2011; 18; 537-543.
Lee K, Lee KB, Jung HY et al. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas. BMC Cancer 2017; 17; 441.
Lee JI, Lee JW, Kim JM et al. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J. Gastroenterol. 2012; 18; 4751-4757.
Aishima S, Kuroda Y, Nishihara Y et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am. J. Surg. Pathol. 2007; 31; 1059-1067.
Liau JY, Tsai JH, Yuan RH et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod. Pathol. 2014; 27; 1163-1173.
Hayashi A, Misumi K, Shibahara J et al. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am. J. Surg. Pathol. 2016; 40; 1021-1030.
Akita M, Fujikura K, Ajiki T et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod. Pathol. 2017; 30; 986-997.
Akita M, Sofue K, Fujikura K et al. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. HPB (Oxf.) 2018; 21; 226-234.
Huang B, Wu L, Lu XY et al. Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR Imaging. Radiology 2016; 281; 150-157.
Vilana R, Forner A, Bianchi L et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51; 2020-2029.
Li R, Cai P, Ma KS et al. Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma. Sci. Rep. 2016; 6; 26772.
Komuta M, Spee B, Vander Borght S et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47; 1544-1556.
Amin MB, Edge S, Greene F eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer, 2017.
Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J. Gastroenterol. 2015; 21; 311-317.
Zhang BL, Ji X, Yu LX et al. Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. Oncol. Lett. 2018; 16; 6003-6012.
Lee SE, Chang SH, Kim WY et al. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma. Oncotarget 2016; 25; 69267-69275.
Ding Z, Shi C, Jiang L et al. Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation. Oncotarget 2017; 8; 114526-114539.
Rebouissou S, Franconi A, Calderaro J et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology 2016; 64; 2047-2061.
Govaere O, Komuta M, Berkers J et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 2014; 63; 674-685.
Moeini A, Sia D, Zhang Z et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J. Hepatol. 2017; 66; 952-961.
Joseph NM, Tsokos CG, Umetsu SE et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J. Pathol. 2019; 248; 164-178. https://doi.org/10.1002/path.5243.